Familial hypobetalipoproteinemia is an autosomal codominant disorder resulting in a dramatic reduction in plasma concentrations of apolipoprotein (apo) B, cholesterol, and ,-migrating lipoproteins. A benefit of hypobetalipoproteinemia is that mildly affected individuals may be protected from coronary vascular disease. We have used gene targeting to generate mice with a modified Apob allele. Mice containing this allele display all of the hallmarks of human hypobetalipoproteinemia: they produce a truncated apoB protein, apoB70, and have markedly decreased plasma concentrations of apoB, ,B-lipoproteins, and total cholesterol. In addition, the mice manifest several characteristics that are occasionally observed in human hypobetalipoproteinemia, including reduced plasma triglyceride concentrations, fasting chylomicronemia, and reduced high density lipoprotein cholesterol. An unexpected finding is that the modified Apob allele is strongly associated with exencephalus and hydrocephalus. These mice should help increase our understanding of hypobetalipoproteinemia, atherogenesis, and the eitiology of exencephalus and hydrocephalus.
Apolipoprotein (apo) B is a major structural component of very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), low density lipoprotein (LDL), chylomicrons, and lipoprotein(a). High plasma levels of apoBcontaining lipoproteins are associated with an increased risk of coronary artery disease (1) . apoB normally exists in two forms, apoB100 and apoB48; both are the product ofthe same gene (2) . The human gene spans 43 kb of DNA and contains 29 exons (3) .
apoBlOO, which contains 4536 amino acids, is synthesized exclusively in the liver and is secreted into the circulation as a surface component of triglyceride-rich VLDL. It is a ligand for the LDL receptor and is responsible for receptormediated clearance of LDL by the liver and other organs.
Amino acids 3146-3159 and amino acids 3357-3368 are thought to be important components of the LDL receptorbinding domain of apoBlOO (4) .
apoB48 is formed as a result of post-transcriptional editing of apoB mRNA, which changes codon 2153 into a stop codon (5, 6) . apoB48 is synthesized in small intestine and is required for the packaging of dietary lipids into chylomicrons. A large percentage of mouse hepatic apoB mRNA is edited, indicating that the mouse probably makes apoB48 in the liver (D. F. Johnson, personal communication). apoB48 lacks the putative LDL receptor-binding domain of apoBlOO and does not interact with the LDL receptor.
In humans, many mutations in the APOB gene have been identified that prevent the translation of full-length apoB proteins (for reviews, see refs. 7 and 8). Such mutations cause familial hypobetalipoproteinemia (HBL), a condition characterized by a reduction in circulating apoB, cholesterol, and ,-lipoproteins. Humans homozygous for "null alleles" have a complete absence of apoB-containing lipoproteins and can be severely affected with symptoms of intestinal fat malabsorption, fat-soluble vitamin deficiency, and neurological problems. The phenotypes of individuals homozygous for mutant APOB alleles leading to the synthesis of truncated apoB proteins are variable (7) (8) (9) (10) . Heterozygotes have onethird to one-half of normal apoB and LDL-cholesterol levels and are almost always asymptomatic. Because of their low cholesterol levels, heterozygotes appear to be protected from coronary vascular disease and have a longer life expectancy (10) . Progress is being made toward understanding atherogenesis by investigating humans and animals that are genetically prone to hyperlipidemia. A valid alternative is to study humans and animals that are genetically protected from cardiovascular disease. With this in mind, we have generated a mouse model of HBL. To do this, we used a sequence insertion vector to disrupt exon 26 of the Apob gene in mouse embryonic stem (ES) cells. Mice carrying this disrupted gene synthesize apoB48 and a truncated apoB (apoB70) but no apoBlOO. The lipoprotein phenotype of the mice is remarkably similar to familial HBL in humans. Quite unexpectedly, however, some of the mice also exhibit exencephalus and hydrocephalus, pathologic features that have never, to our knowledge, been reported in human HBL.
MATERIALS AND METHODS Preparation of Targeting Constructs. An =l11-kb Bgl II fragment containing exon 26 of the Apob gene was isolated from STO cell DNA (11) . Two oligonucleotides which encode peptides of human f3s-globin (amino acids 1-12 and 120-131) were used to replace nucleotides located in exon 26 of the Apob gene (see Fig. 1 Targeting of the Apob Locus in Mouse ES Cells. Electroporation of the targeting constructs into the HPRT-ES cell line E14TG2a (13) and selection ofHPRT+ cells was as previously described (14, 15) . ES cells surviving the selection procedure were screened for targeted recombination by PCR essentially as described (16) , using a human jBs-globin sequence-specific primer and an Apob sequence-specific primer (see Fig. 1C ). PCR-positive ES cell colonies were expanded and genomic DNA was prepared for Southern blot analysis. Blots were hybridized to a 32P-labeled probe from outside the targeting construct (probe A, Fig. 1A) , to a probe from within the targeting construct (probe B, Fig. 1A ), or to a plasmid probe (probe C, Fig. 1B Lipoproteins were fractionated by sequential density ultracentrifugation (18) . Fractions were concentrated and desalted by using a Centricon-10 (Amicon) apparatus according to the manufacturer's protocol, and 20 ,ug of protein from each fraction was electrophoresed on an SDS/3-20% polyacrylamide gradient gel (16 x 16 x 1.5 mm) at 150 V for 6 hr (18) . The size of lipoproteins in the d (density) < 1.006 g/ml fraction of mouse plasma was assessed by electron microscopy (19) . Whole plasma apoAI concentrations were quantified by nonreducing gel electrophoresis as described by France et al. (20) .
Northern Blot Analysis. Total RNA was prepared, electrophoresed, transferred to Hybond-N (Amersham), and hybridized as described (21) . Probes used include probes A, B, C (see Fig. 1 ), apoAl (22) , and human j3actin (Clontech).
RESULTS AND DISCUSSION
Targeting of the Apob Locus in Mouse (Fig. 2A) . In addition to these bands, we also detected, with probe B, a 16.0-or 16.5-kb fragment (depending on the orientation of HPRT) and a 17.5-kb Bgl II fragment in all six targeted cell lines (Fig. 2B) . The size of this largest fragment and its intensity indicated that multiple tandem copies of the targeting construct had been integrated (see Fig. 1C ). Such tandem incorporation of multiple copies of incoming DNA into a targeted locus has been reported by others (15, 23, 24) .
All used to generate animals, and the structure of the modified locus was determined by using DNA isolated from mice homozygous for the alteration. By PCR amplification followed by restriction enzyme digestion of the PCR products, we were able to establish (data not shown) that ESapoB6-3 contains three repeats of Apob sequences at the targeted locus, each having LDL receptor-binding domains that have been changed to Is-globin sequences (Fig. 1C) .
Since a stop codon is present in all three of the 5' 3s-globin sequences, this modified Apob allele should always produce a transcript that contains this premature translation termination codon at position 3145 (human equivalent) even if alternative splicing of the mRNA occurs. It should not have a leaky phenotype such as has been suggested to occur after disruption of the N-myc (25) and cystic fibrosis (26) genes; rather it should result in an apoB protein approximately 70% the size of apoBlOO. The translation termination codon should not alter the size of apoB48.
A Truncated ApoB, ApoB70, Is Produced from the Modified Allele. SDS/polyacrylamide gel electrophoresis of the VLDL and IDL/LDL fractions from wild-type mice reveals apoB48 and apoBlOO (Fig. 3) . In contrast, the VLDL and IDL/LDL fractions from homozygous mutants contain no detectable apoBlOO; only apoB48 and a truncated apoB are observed.
We estimate the size of this truncated apoB protein to be -70% the size ofapoB100 on the basis of the observation that the truncated apoB migrates slightly faster than human apoB74, a proteolytic product of apoBlOO (data not shown).
We will refer to the truncated apoB as apoB70. The VLDL and IDL/LDL fractions from heterozygous mice contain all three apoB proteins, B48, B70, and B100. It should be noted that in the IDL/LDL fraction from heterozygous mice, the amount of apoB70 is approximately 9% the amount of apoBlOO. Also, in heterozygous mice the amount of apoB48 relative to apoBlOO is increased. This parallels similar observations in humans who are heterozygotes for apoB67 and apoB83 mutations (27, 28) . We estimate that apoB48 levels in homozygous mice are reduced by one-half relative to normal. The intensities of staining of apoB48 in the IDL/LDL fractions of wild-type and homozygous mice are nearly equal in Fig. 3 , but twice the amount of sample was loaded in the latter. Thus, our apoB mutation results in the production of VLDL IDL/LDL HDL --+l +1--X-+1 +X-/X +1+ +1-/X apoB100-_ apo B70 _ apo B48 --_ apo E -_ apoAl -_ a small amount of apoB70, and about half the normal amount of apoB48. This finding is identical to the situation in humans with HBL, where truncated apoB proteins are invariably present in very low concentrations (7) .
To investigate the mechanism responsible for the reduced amount of plasma apoB proteins, we examined the amount of apoB mRNA in small intestine and liver. This analysis showed that wild-type and heterozygous mice have similar amounts of apoB mRNA (Fig. 4A) ; in contrast, the amounts of apoB mRNA in small intestine and liver of homozygous mice are only 25% and 40%, respectively, of the amounts in wild-type or heterozygous mice, as estimated by densitometry of the Northern blot. The size of the apoB mRNA (=14 kb) transcribed from the modified allele is similar to that from the unmodified allele. However, probe A, which is 3' to the site of insertion of the targeting construct, does not hybridize to the apoB message from homozygous mice (Fig. 4B) , and probe C, which detects plasmid-related sequences, hybridizes to mRNA from heterozygous and homozygous mice only (Fig. 4C) . Thus, the transcript of the mutant allele appears to terminate in the inserted DNA. Therefore, the modified and unmodified alleles produce distinctly different transcripts even though the sizes appear similar. The difference in the level of the mutant apoB mRNA could be the result of differences in mRNA stability caused by the inserted sequences and/or insertional disruption of (unknown) transcriptional regulatory sequences. Irrespective of the cause of the reduced quantity of apoB mRNA, it is at least one factor that leads to the reduced amount of apoB proteins in mice homozygous for the modified Apob allele.
HBL in Mice Homozygous for the Modified Apob Allele. Agarose gel electrophoresis of total plasma from wild-type mice shows that the majority of plasma lipoproteins migrate as three distinct bands at the a, f, and pre-13 positions (Fig.  5) . Electrophoresis of total plasma from the homozygous mutants reveals a virtual absence of (3-migrating lipoproteins. (Fig. 5) .
Agarose gel electrophoresis of the plasma also reveals that fasted homozygous mice have chylomicronemia, as evidenced by accumulation of stained lipids at the origin of the gel (Fig.  5 ). This finding is not observed in heterozygous or wild-type mice. Steinberg and co-workers (9) have reported fasting chylomicronemia in a human with HBL; and plasma from Steinberg's human subject, a compound heterozygote with one mutant allele yielding apoB37 and another mutant allele yielding apoB86 (29) , is compared with the mouse plasma in Fig. 5 to illustrate this. The cause of the fasting chylomicronemia in the homozygous mice or in the human compound heterozygote is not immediately obvious. Since neither the targeted modification that we created nor the apoB86 mutation of Steinberg's patient is expected to interfere with the function of apoB48, it might be expected that chylomicrons would be packaged, transported, and metabolized normally. It is important to note that the lipoproteins at the origin ofthe agarose gel may not be "chylomicrons" but instead may be hepatic lipoproteins or a mixture of hepatic and intestinal lipoproteins. This topic warrants further investigation.
The finding of chylomicronemia led us to examine, by electron microscopy, the size distribution of lipoprotein particles with densities less than 1.006 g/ml. The fractions of large particles (>70 nm) in wild-type, heterozygous, and homozygous mice were 0.8%, 0.6%, and 1.8%, respectively. The mean (±SD) diameters of the d < 1.006 g/ml particles in wild-type, heterozygous, and homozygous mice were virtually identical: 41.34 ± 9.56, 38.98 ± 9.26, and 39.66 ± 9.64 nm, respectively. Thus, similar to human apoB37/apoB86 compound heterozygotes (9) , homozygous mutant mice also have a normal VLDL diameter but a skewing toward larger particles.
The modified Apob allele affects circulating concentrations of cholesterol in a co-dominant manner ( Table 1 ). The concentrations of total and HDL cholesterol in the plasma of fasted homozygous mice are reduced to =50% of the normal levels. The concentrations of total and HDL cholesterol in heterozygous mice are also significantly less than that in wild-type mice. The reduction of HDL cholesterol levels in homozygous mice is also reflected in a reduction in apoAI levels of -45% as determined by nonreducing gel electrophoresis of whole plasma (data not shown). Since apoAl is the major protein component of HDL, the reduced levels of apoAI could possibly account for the reduced HDL cholesterol levels. However, we noted that the amount of apoAI mRNA is not reduced in homozygotes and may even be increased in small intestine (Fig. 4D) . Thus, increased ca- tabolism of HDL (and apoAI) may be responsible for the reductions in HDL cholesterol and apoAI. In human HBL homozygotes, HDL concentrations have been variable, ranging from low to elevated (7) (8) (9) (10) .
The concentration of triglyceride in plasma is also reduced in a dominant manner by the modified Apob allele (Table 1) . A reduction in plasma triglycerides in human heterozygotes has been observed in many studies (27, 30, 31) .
Exencephalus and Hydrocephalus Are Associated with the Modified Apob Allele. During our analysis of the genotypes of 21-day-old mice from heterozygote crosses, we noted significantly fewer homozygotes than expected based on the 1:2:1 Mendelian ratios of wild type:heterozygotes:homozygotes. We observed 108 wild-type mice, 239 heterozygotes, and only 58 homozygotes (X2 = 25.5, P < 0.0001). To investigate the reason for the deficiency of homozygotes, we examined 47 fetuses (day 15.5-19.5 of gestation) derived from mating homozygous males with heterozygous females. Thirteen were exencephalic; all proved homozygous for the modified Apob allele. Thus, the deficiency of homozygotes at weaning appears to be due to perinatal mortality associated with exencephalus.
Some mice that survive to weaning develop hydrocephalus. This abnormality is characterized externally by a large, dome-shaped head that is usually detected between 3 and 6 weeks of age. Gross dissection and histological analysis of the brain of several of the hydrocephalic mice indicate that fluid accumulation is confined to the lateral and third ventricles. Genotype analysis reveals that by 8 weeks of age, hydrocephalus is detected in 32% (24/75) of homozygotes, in 1% (3/234) of heterozygotes, and in 0o (0/91) of wild-type littermates. Unaffected homozygotes usually survive to maturity, appear healthy, and reproduce, but some of their offspring can be exencephalic or hydrocephalic.
Exencephalus and hydrocephalus have not been reported in humans with abetalipoproteinemia or HBL and, at this stage, we have no direct evidence that abnormalities in lipid metabolism are the cause of the morphological abnormalities in our mice. For example, since only one targeted ES cell line was used to generate animals, we cannot exclude the possibility that a mutation was introduced in an unidentified gene that is linked to the Apob locus. It is also conceivable that overexpression of the HPRT genes introduced into the Apob locus affects purine metabolism during development. It is also possible that insertion of 35 kb of DNA into the Apob locus has affected the function of nearby genes involved in development of the brain. However, the most plausible explanation of these morphological abnormalities is that they are caused by deficiency of one or more fat-soluble vitamins that is secondary to the lack of LDL. For example, vitamin E is a lipid-soluble vitamin that is transported in the body as part of LDL. Humans with abetalipoproteinemia and human HBL homozygotes often manifest clinical symptoms of vitamin E deficiency (10) . This deficiency leads to neuromusProc. Natl. Acad. Sci. USA 90 (1993) cular and retinal degeneration and can be alleviated by massive oral supplementation with vitamin E. In laboratory animals, maternal vitamin E deficiency has been shown to cause exencephalus and hydrocephalus in offspring (32, 33) , and we have preliminary data indicating that our adult homozygous mice have plasma levels of a-tocopherol approximately 35% of those observed in wild-type mice (G.E.H. and M. Traber, unpublished observations). The effects of the Apob gene modification on the metabolism of fat-soluble vitamins in these mice bear further investigation.
Conclusion. We have used gene targeting in ES cells to create a mouse model of familial HBL. The HBL mice manifest the hallmarks that define this condition in humans. They have very low concentrations of cholesterol and the j-lipoproteins, and they synthesize a truncated form of apoB. All apoB proteins are present in very low levels in the plasma. The mice also exhibit several characteristics observed in some HBL humans: reduced HDL cholesterol levels, reduced plasma triglyceride concentrations, fasting chylomicronemia, and symptoms suggesting vitamin E deficiency. Therefore, these mice represent a useful model for investigating how truncated apoB proteins alter lipoprotein metabolism.
HBL mice will be a useful model for investigating the effects of this condition on the development of atherogenesis. The lipoprotein profile in these mice is expected to be protective from fatty streak formation and atherosclerosis. This mouse model will permit us to test this expectation by using a genetic approach. Mice with HBL can be mated with mice carrying mutations in additional genes involved in lipoprotein metabolism. For example, mice homozygous for a disrupted Apoe allele are hypercholesterolemic and spontaneously develop atherosclerotic lesions (18, 34) . It will be of great interest to evaluate whether the dominant effect of the Apob gene modification will overcome the effect of the apoE deficiency in mice with combined defects and protect them from hyperlipidemia and atherosclerosis. Information gained from studying this animal model of HBL could eventually lead to therapies (drug and/or gene) to inhibit the atherosclerosis disease process.
We also observed that the modified Apob allele is strongly associated with the morphological abnormalities exencephalus and hydrocephalus. This may be the first example of a known genetic alteration that causes, probably indirectly, the congenital abnormalities exencephalus and hydrocephalus.
While all forms of these abnormalities are unlikely to be due to changes in the Apob gene itself, a portion of them could be due to disturbances in lipid metabolism. The regular development of exencephalus and hydrocephalus in these mice provides a model for investigating the development and the pathogenesis of a disorder that affects a substantial number of human newboms.
We 
